Major Affective Disorder 2

12/01/1993 - "Given the critical role of PKC in regulating neuronal signal transduction, lithium's effects on PKC in the limbic system represent an attractive molecular mechanism for its efficacy in treating both poles of manic-depressive illness. "
06/01/1998 - "Future studies are therefore need to determine whether allelic variants of the INPP1 gene are associated with a favourable efficacy of lithium in manic-depressive illness."
09/01/2001 - "Lithium (Li+) was chosen because it is an efficient treatment for manic-depressive illness, with an unknown action mechanism. "
01/01/1994 - "Despite extensive research, the underlying biologic basis for the therapeutic efficacy this drug remains unknown, and in recent years, research has focused on signal transduction pathways to explain lithium's efficacy in treating both poles of manic-depressive illness. "
06/26/1971 - "Efficacy of lithium as acute treatment of manic-depressive illness."

12/01/1983 - "Prophylactic efficacy of carbamazepine in manic-depressive illness."
01/01/1981 - "A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness."
01/01/1994 - "A 43 year-old female patient with a history of manic-depressive illness and prophylactic carbamazepine (CBZ) medication ingested a potentially lethal overdose of 20 g of the substance. "
12/01/1985 - "Are the psychotropic effects of carbamazepine in manic-depressive illness mediated through the limbic system?"
01/01/1985 - "This effect may be related to the therapeutic action of carbamazepine in manic depressive illness."

11/01/1988 - "The use of anticonvulsants in manic-depressive illness."
11/01/1988 - "The role of anticonvulsants, particularly carbamazepine, in the treatment of manic-depressive illness has been the subject of multiple recent studies. "
06/01/1997 - "The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness."
08/01/1984 - "Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study."
04/01/1984 - "Carbamazepine, a potent anticonvulsant for temporal lobe and limbic seizures in animals and man, inhibits amygdala-kindled seizures and is effective in the treatment of manic-depressive illness. "

03/01/1989 - "experience with valproate in manic depressive illness: a multicenter trial."
04/01/2007 - "Valproic acid (VPA) is widely used to treat epilepsy and manic-depressive illness. "
02/01/1998 - "For the patient with migraine and epilepsy, or migraine and manic depressive illness, divalproex sodium is the drug of choice. "
03/01/1989 - "Recent preliminary research demonstrates the effectiveness of valproate in the treatment of manic-depressive illness, including acute mania, prevention of bipolar episodes, and schizoaffective disorder. "
01/01/2004 - "Lithium and valproate are chemically unrelated compounds that are used to treat manic-depressive illness. "

06/01/1979 - "The efficacy of lithium carbonate as a treatment for manic-depressive illness has stimulated a reevaluation of the syndrome. "
08/01/1976 - "Eleven patients in remission from manic-depressive illness were studied by means of metabolic balances before and after the administration of lithium carbonate. "
03/01/1973 - "Prophylactic efficacy of lithium carbonate in manic-depressive illness. "
10/01/1977 - "II. Therapeutic trial of lithium carbonate and further description of manic-depressive illness in children."
09/01/2005 - "Lithium carbonate used in the long-term treatment of manic-depressive illness has been reported to lead to progressive renal impairment in rats and humans. "

04/01/2017 - "Antidepressant-induced Dopamine Receptor Dysregulation: A Valid Animal Model of Manic-Depressive Illness."
01/01/1986 - "These preliminary data suggest that carbamazepine has some acute antidepressant efficacy in addition to the growing evidence that it has acute antimanic and longer-term prophylactic efficacy in both phases of manic-depressive illness."
01/01/1985 - "The reduction of +5V to +4V by antidepressants would diminish the binding of +5V to the ATPase and could account for some of the therapeutic action of the drugs in manic-depressive illness."
03/01/1984 - "The Cholinergic-Monoaminergic Interaction Theory of antidepressant withdrawal induced activation and of rapidly-cycling manic-depressive illness maintains that system 'A' and a cholinergic inhibitory system interact dynamically, and that excessive monoaminergic function can precipitate excessive cholinergic function and a dearth of monoaminergic function (due to autoregulation) and hence depression. "
04/01/1979 - "Effects of the potential antidepressant AHR-1118 on amine uptake and on plasma 3-methoxy-4-hydroxyphenylglycol in manic-depressive illness [proceedings]."

05/01/1994 - "Our results suggest that, in manic-depressive illness, there might be abnormalities in the metabolism of neutral amino acids, mainly of TRP and TYR, and that abnormality of TRP might be related to the depressive symptoms, and that plasma TRP and TYR ratios might be important indicators for determining the efficacy of some anti-manic and anti-depressive drugs."
09/01/1992 - "These results suggest that, in manic-depressive illness, there might be abnormalities in the metabolism of neutral amino acids, mainly of TRP and TYR, and that the plasma TRP and TYR ratios might be important indicators for determining the efficacy of some drugs."
05/01/1994 - "[Analysis of plasma amino acids-tryptophan and tyrosine ratios to other large neutral amino acids in manic-depressive illness]."
05/01/1994 - "On the basis of the hypothesis of the brain monoamine metabolism abnormality in manic-depressive illness, plasma tryptophan (TRP) ratio, an indicator of brain 5HT level, and the ratios of other neutral amino acids (tyrosine (TYR), valine, isoleucine, leucine, and phenylalanine) were determined in manic and depressed patients. "

01/01/1997 - "Several studies have implicated the tyrosine hydroxylase (TH) locus within the 11p15 region in susceptibility to manic depressive illness (MDI). "
01/01/1997 - "Manic depressive illness and tyrosine hydroxylase gene: linkage heterogeneity and association."
08/03/1996 - "Manic-depressive illness and tyrosine hydroxylase gene."
06/08/1996 - "Manic-depressive illness and tyrosine hydroxylase markers. "
05/27/1995 - "Tyrosine hydroxylase gene and manic-depressive illness."

04/01/1982 - "It is conceivable 6Li may have a greater toxic or therapeutic effect than 7Li in the treatment of manic-depressive illness."
09/01/1976 - "From these results, it is likely that the inhibitory effect of LiCl on the MAPT and Ro-1284-induced changes in NE and DA metabolism may to some extent be involved in the therapeutic effects on manic-depressive illness."
03/01/2000 - "For several decades, lithium has been the drug of choice in the long-term treatment of manic-depressive illness, but the molecular mechanism(s) mediating its therapeutic effects remain to be determined. "
06/01/1986 - "Brain 5-HT receptors are reported to play an important role in the therapeutic effect of Li in manic-depressive illness. "
01/01/1983 - "Evidence of its therapeutic effects in lithium-resistant manic-depressive illness and schizoaffective illness is reviewed. "

06/01/1998 - "This enzyme is Li+ sensitive, and is one of the proposed targets of Li+ therapy in manic-depressive illness. "
01/01/1995 - "We have previously reported possible evidence for linkage between manic depressive illness and the locus at 16p13.3 encoding the enzyme phosphoglycolate phosphatase (PGP), in the larger of two Danish families. "
11/01/1993 - "Suggestion of linkage between manic-depressive illness and the enzyme phosphoglycolate phosphatase (PGP) on chromosome 16p."
08/20/1986 - "The monovalent lithium ion inhibits the enzyme myo-inositol-1-phosphatase at concentrations comparable to those which are useful in the treatment of manic depressive illness. "
01/01/1998 - "This association study explores whether the tryptophan hydroxylase (TPH) gene, which codes for the rate-limiting enzyme of serotonin biosynthesis, is a susceptibility factor for manic-depressive illness, with or without a history of suicide attempts. "

07/01/1977 - "The possible relevance of the results of this study to manic depressive illness and Li therapy is discussed."
06/01/2004 - "Lithium therapy is a widely used pharmacological treatment of manic-depressive illness, which both stabilizes the ongoing episodes and prevents relapses. "
06/01/1998 - "This enzyme is Li+ sensitive, and is one of the proposed targets of Li+ therapy in manic-depressive illness. "
08/01/1996 - "The hypothesis that lithium is the most appropriate and efficacious pharmacological treatment in the therapy of manic-depressive illness was examined in a meta-analysis. "
11/01/1995 - "Lithium therapy in the treatment of manic-depressive illness. "

01/01/2002 - "The broadening of the classification systems for manic-depressive illness towards a spectrum of bipolar disorders implicates a more differentiated use of pharmacotherapies. "
02/01/1989 - "Lithium is widely used in psychiatric chemotherapy and is especially effective in the treatment of manic-depressive illness (MDI), but the mechanism for its therapeutic properties and side effects remains to be elucidated. "
06/01/2000 - "Lithium is a well established pharmacotherapy for the treatment of recurrent manic-depressive illness. "
06/01/1989 - "The classification of muscarinic receptors into M1 and M2 subtypes and the involvement of guanine nucleotide binding proteins (G-proteins) as major mediators of receptor information transduction in the cholinergic and other neurotransmitter systems have prompted us to undertake studies both at receptor and postreceptor levels that may shed light on the importance of these new findings to the pharmacotherapy of manic-depressive illness and of extrapyramidal syndromes. "

09/01/1991 - "Relapse prevention in manic depressive illness: important and unimportant factors."
06/01/1983 - "Lithium and relapse prevention in manic-depressive illness."

05/01/1988 - "As well, seasonal affective disorder--a depression occurring in winter, is reported to respond to light therapy and it has been proposed that supersensitivity to light is a trait-marker of manic-depressive illness. "

09/01/1980 - "Length of stay was extremely long for schizophrenic and manic depressive illness and relatively short for cerebrovascular syndromes. "